Report of Foreign Issuer (6-k)
May 18 2015 - 6:13AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of May, 2015
Commission File Number
Novogen
Limited
(Translation of registrant’s name into English)
16-20 Edgeworth David Ave, Hornsby, NSW 2077, Australia
(Address of principal executive office)
Indicate by check mark whether
the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F þ Form 40-F ¨
Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ¨
Note: Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K if submitted
solely to provide an attached annual report to security holders.
Indicate by check mark if the registrant is submitting the Form 6-K in paper as
permitted by Regulation S-T Rule 101(b)(7): ¨
Note: Regulation S-T Rule 101(b)(7) only
permits the submission in paper of a Form 6-K if submitted to furnish a report or other document that the registrant foreign private issuer must furnish and make public under the laws of the jurisdiction in which the registrant is incorporated,
domiciled or legally organized (the registrant’s “home country”), or under the rules of the home country exchange on which the registrant’s securities are traded, as long as the report or other document is not a press release, is
not required to be and has not been distributed to the registrant’s security holders, and, if discussing a material event, has already been the subject of a Form 6-K submission or other Commission filing on EDGAR.
Indicate by check mark if the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission
pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934. Yes ¨ No þ
If “yes” is marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b)
|
|
|
|
|
| ASX:NRT
NASDAQ:NVGN
Novogen Ltd (Company)
ABN 37 063 259 754
Capital Structure
Ordinary Shares on issue:
361 M
Board of
Directors Dr Graham Kelly
Chairman & Executive Director
Steve Coffey Non Executive Director
John O’Connor
Non Executive Director
Prof Peter Gunning Non Executive Director |
|
MARKET RELEASE 18 May
2015 NOVOGEN TO PRESENT AT HONG KONG INVESTOR CONFERENCE
May 18 2015, Sydney, Australia: US-Australian
drug discovery and development company, Novogen Limited (ASX:NRT; NASDAQ:NVGN), announced today that company CEO, Dr Graham Kelly, will be a presenting company at Asia Biotech Invest 2015 May 20-21.
The Novogen presentation is at 10.00 am May 20 at the Sheraton Hotel and Towers, Hong
Kong. The event is co-delivered by AusBiotech and Beacon Events, and supported by
partners including ChinaBio Group, HKBio, ASX and Austrade. Information about the
program, speaker line up and spotlight company presentations is available at www.asiabiotechinvest.com
Novogen CEO, Graham Kelly, said, “This week represents our inaugural exposure of the Company to the Asian investment market. A review of our share
registry has revealed a growing and significant level of shareholding out of Asia, so the conference presents a timely opportunity to start highlighting the Novogen story to this enormous investment market. The conference presentation will be
accompanied by a road-show to institutional investors in Hong Kong. With our need for funds well on the way to being satisfied, it is now a case of highlighting the investment opportunity by on-market buying in the Company’s two first-in-class
technology platforms.” About Novogen
Novogen is a public, Australian-US drug development company whose shares trade on both The
Australian Securities Exchange (NRT) and NASDAQ (NVGN). The Novogen group includes US-based, CanTx Inc, a joint venture company with Yale University. Novogen has two drug technology platforms yielding drug candidates that are first-in-class with
potential application across a broad range of degenerative diseases. In the oncology field, the ultimate objective is to see both drug technologies used in combination as first-line therapy across most forms of cancer, with the objective of
preventing tumor recurrence. This objective is based on a strategy of achieving comprehensive destruction of the full hierarchy of cells within a tumor with the super-benzopyran technology platform killing the tumor-initiating cells and the
anti-tropomyosin technology, combined with vinca alkaloids, to deliver a potent chemical debulking effect on their daughter cells.
For more information, please visit www.novogen.com |
|
|
|
| Corporate Contact Dr. Graham Kelly
Executive Chairman & CEO Novogen Group
Graham.Kelly@novogen.com +61 (0) 2 9472 4101 |
|
Media Enquiries Prue Kelly
Media Officer Novogen Group
Prue.Kelly@novogen.com +61 (0) 2 9472 4101 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
Novogen Limited (Registrant)
Lionel Mateo
Lionel Mateo
Company Secretary
Date 18 May 2015
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jun 2024 to Jul 2024
Kazia Therapeutics (NASDAQ:KZIA)
Historical Stock Chart
From Jul 2023 to Jul 2024
